Evaluation of low-dose cytarabine therapy in myelodysplastic syndromes.
Myelodysplastic syndromes (MDS) are a group of disorders characterised by progressive cytopenias and impaired maturation of haematopoietic cells. It carries a high mortality due to severe infections and/or bleeding, and transformation into acute myeloid leukaemia (AML). Its treatment is largely unsatisfactory except a few favorable reports with low-dose cytarabine therapy, which has recently created a widespread enthusiasm for its use.
el Mangoush
M
M
Medicine Dpt., Hawari Hospital, Arab Medical University, Benghazi, Libya.
Singh
M K
MK
Kumar
S
S
Korajkio
M
M
Gamati
A
A
D000368:Aged; D003561:Cytarabine / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
D003561:Cytarabine